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Abstract: Background: Asthma is principally managed in general practice. Appropriate prescribing
and medication use are essential, so general practice pharmacists appear suitable to conduct asthma
management consultations. This pilot study aimed to evaluate the asthma management role of a
pharmacist in general practice. Methods: Analysis of an activity diary and stakeholder interviews
were conducted to identify interventions in asthma management; determine whether asthma
control changed following pharmacist input; and determine acceptability of asthma management
review by a pharmacist in one general practice in Canberra, Australia. Results: Over 13 months,
the pharmacist saw 136 individual patients. The most common activities were asthma control
assessment; recommendations to adjust medication or device; counselling on correct device use;
asthma action plan development and trigger avoidance. For patients with multiple consultations,
the mean Asthma Control Test score improved from the initial to last visit (14.4 ± 5.2 vs. 19.3 ± 4.7,
n = 23, p < 0.0001). Eight of the 19 (42%) patients moved from having poor to well-controlled
asthma. Case studies and qualitative data indicated probable hospital admission avoidance and
stakeholder acceptability of asthma management by a practice pharmacist. Conclusions: This pilot
study demonstrated it is feasible, acceptable and potentially beneficial to have a general practice
pharmacist involved in asthma management. Fuller evaluation is warranted.
Keywords: primary health care; asthma; general practice; pharmacists; patient education
1. Introduction
Asthma is a common chronic condition that is principally managed in general practice.
A 2014–2015 survey determined that of the 10.8% of Australians who had asthma, almost two-thirds
(60.9%) had consulted a general practitioner (GP) in the previous 12 months for their condition and
6.0% had consulted a specialist [1]. However, one in four of the asthma patients surveyed reported
poor symptom control over the previous 12 months [1], so there may be scope for improvement of
asthma management in general practice. Reasons identified for possible suboptimal management
included variable adherence to prescribing guidelines and poor utilisation of asthma action plans [2].
Improved asthma control is associated with better quality of life, increased productivity and savings to
the health system [3].
Incorrect medication selection and use can lead to poor asthma management and adverse
outcomes [4–6]. Pharmacists have demonstrated that they can improve asthma control through
increasing the appropriate use of medication [7]. Given that most of the asthma care is delivered
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in general practice, pharmacists in this setting may provide an opportunity to work collaboratively
with GPs, nurses and other healthcare professionals to improve asthma management. While not as
developed as in the United Kingdom, the role of pharmacists in general practice is becoming more
established in Australia. This was recognized by the Australian Government, who announced some
funding via The Workforce Incentive Program in 2018 [8]. It was identified that one of the practice
pharmacists’ roles would be supporting patients with chronic health conditions [8]. This is consistent
with other countries such as England [9]. The National Health Service (NHS) in England states that
one of the aims of the clinical pharmacist in general practice is to manage patients with long-term
conditions [9].
General practices in Australia are encouraged to engage with asthma patients via the Asthma
Cycle of Care, a Medicare Benefits Schedule (MBS) claimable activity for GPs. This comprises two
asthma-related consultations within a 12-month period for patients diagnosed with moderate to severe
asthma. An Asthma Cycle of Care requires a documented diagnosis, assessment of asthma control
and severity, a review of the patient’s use and access to asthma medication and devices, development
and subsequent review of a written asthma action plan, and asthma self-management education [10].
The severity of asthma at a point in time can be determined by administering the Asthma Control
Test (ACT). The ACT is a patient questionnaire about symptoms, medication use, quality of life and
perceived control over the previous 4 weeks. Each of the five questions is assigned a minimum
score of 1 and a maximum score of 5, providing a total score between 5 and 25. An ACT score of 19
or below indicates that asthma management needs improvement, while 20 or more indicates good
control [11,12].
Practice nurses usually conduct the Asthma Cycle of Care activities, but pharmacists also possess
the necessary skills. The aim of this pilot study was to describe interventions in asthma management
by one general practice pharmacist, subsequent changes in asthma control and the acceptability of
this model of care. This study was nested within a trial conducted in the Australian Capital Territory,
Australia [13,14], which was funded by the Capital Health Network, the local Primary Health Network.
2. Materials and Methods
Five part-time (15.2–16 h per week) non-dispensing pharmacists were employed by three general
practices in the Australian Capital Territory from February 2016. The three practices recruited their
own pharmacists without any involvement of the research team, and they had not previously had
a pharmacist within the practice. The pharmacists were subsequently utilized according to their
own individual skillset and local workplace needs, as independently determined by each practice.
Each general practice pharmacist maintained a daily activity diary, the analysis of which has been
described elsewhere [13]. Stakeholder experiences with the pharmacists in general practice have also
been published [14].
A sub-analysis of the activity diary from one of the pharmacists, who had selected asthma
management as an area of focus, and the stakeholder perspectives were conducted to identify which
interventions were conducted; determine whether asthma control had improved following pharmacist
input, by comparing ACT results at the initial consultation with those at following consultations;
and to determine the acceptability of a general practice pharmacist in asthma management.
The initial sub-analysis of the activity diary was conducted by one researcher (AM) and checked
by two other researchers (LD, SK). Changes in ACT scores (first to last consultation) were compared
for each individual using a paired t-test, while the Fisher’s exact test was used to examine changes in
the distribution of patients across categories of asthma control.
Feedback about pharmacist-provided asthma care was obtained from the semi-structured
interviews that were conducted by one researcher (LD) with patients, GPs and the practice pharmacist.
These interviews were audio-recorded and transcribed verbatim by a professional transcribing agency,
with LD checking the transcripts for accuracy. The transcripts were imported into NVivo (version
10.2.2, QSR, Melbourne, VIC, Australia). Two researchers (LD, SK) conducted the thematic analysis by
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reading the transcripts and adding codes to the data to identify emerging themes that described the
data. Each researcher worked independently initially to reduce any bias, then agreed on emerging
themes and resolved any discrepancies by discussion.
Case studies were identified in consultation with the practice pharmacist. The University of
Canberra Human Ethics Research Committee approved the study (Project number 15-235).
3. Results
3.1. Activity Diary
Activity diary data was collected from 23 May until 25 November, 2016 and from 15 May until
15 December, 2017. Patients with asthma were either identified and invited to attend for review by the
practice pharmacist or referred to the practice pharmacist by the GPs or other members of practice staff.
GPs, nurses and receptionists suggested that patients consult with the practice pharmacist if they had
concerns about asthma control, compliance with inhalation devices, device selection or requirements
for training in device use. The patients’ ages ranged from 17 months to 84 years.
3.1.1. Interventions by the Pharmacist
Overall, 87.5% (119/136) patients who consulted with the practice pharmacist had their asthma
control recorded on their first visit and, in general, they had relatively poor asthma control (mean
ACT score of 18 ± 5.3; Table 1). The pharmacist conducted activities such as issuing asthma
action plans, educating patients, recommending to step up/down therapy, reviewing inhaler
technique and making other relevant recommendations such as device changes (e.g., dry-powder to
metered-dose inhaler). Step up of therapy comprised increasing or starting corticosteroid/long-acting
beta agonist combination inhaler; corticosteroid inhaler; short-acting muscarinic antagonist inhaler;
oral corticosteroid; oral montelukast; or long-acting muscarinic antagonist inhaler. Step down of
therapy comprised reducing or stopping corticosteroid/long-acting beta agonist combination inhaler;
corticosteroid inhaler; or long-acting muscarinic antagonist inhaler. Asthma plans were provided and
discussed with all patients. The pharmacist made comprehensive entries into the patients’ clinical notes
and discussed prescribing recommendations, the ACT results and the asthma plans with each patient’s
GP during or as soon as possible after the consultation. Follow up consultations were arranged with
the GP, pharmacist or nurse to monitor progress with alterations to management where necessary.
Data from the practice pharmacist asthma consultations is shown in Table 1. Illustrative case studies
are provided in Appendix A.
For patients below 6 years of age, the pharmacist mainly talked with the accompanying adult, but
involved the children as much as possible. The pharmacist tried to make it fun and engaging for the
child e.g. showed pictures or used drawings. The pharmacist also gave stickers that could be placed
on inhalers if the child answered questions correctly. Educational games/videos/apps were used for
different age groups. Teenagers were usually given an emergency spacer (flat paper spacer) for when
they were going out.
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Table 1. Summarised data from the practice pharmacist asthma consultations.
Consultations ACT Values(Mean± SD)
Number of consultations 166
Number of patients 136
Age (years): mean ± SD 33 ± 25 *
Gender of patients 87 females, 47 males *
Number of consultations with asthma
action plan issued or reviewed 144 (86.7%)
Number of patients with ACT score
recorded on first visit 119 (87.5%) 18 ± 5.3
Number of consultations where step
down of therapy was recommended 25 (15.1%) 21 ± 4.0
Number of consultations where step
up of therapy was recommended 37 (22.3%) 14 ± 5.2
Number of consultations where
device change was recommended 22 (13.3%)
Number of consultations where
spacer was added 40 (24.1%)
Number of consultations where
advice about allergy management
was given
14 (8.4%)
Number of consultations where
advice about managing adverse drug
reactions was given
12 (7.2%)
Number of consultations where
smoking cessation advice was given 7 (4.2%; all the smokers in the cohort)
Number of consultations where other
interventions were made ( n=/ < 5
for each)
exercise(5), thunderstorm asthma(3), referral for bone
mineral density measurement(2), recommending
influenza vaccination(2), influenza vaccine
administration(1), peak flow monitoring(1), sleep
hygiene advice(1), spirometry testing(1), prioritising
treatment due to cost of medications(1)
* 2 not specified.
3.1.2. Changes in ACT Scores Following the Pharmacist’s Interventions
A subset of 26 patients (19.1%) were seen more than once by the pharmacist during the data
collection periods. Following the pharmacist’s interventions, ACT scores improved for 19 patients,
worsened for three patients, were unchanged for one patient and data was incomplete for three patients.
The mean ACT score for this subset of patients was 14.4 (SD = 5.2) at the first visit and 19.3 (SD = 4.7)
at the most recent visit (n = 23, t = 5.43, p < 0.0001). Prior to the pharmacist review, 17% (4/23) patients
had good asthma control (ACT > 19), increasing to 52% (12/23) afterwards (Fisher’s exact test p = 0.03).
In total, 42% (8/19) patients with poor control moved to well-controlled asthma following review by
the practice pharmacist.
3.2. Perceptions of Asthma Care Provided by Practice Pharmacist
The themes and data demonstrated that asthma care by the practice pharmacist was acceptable
to patients, GPs and the practice pharmacist (see Table 2). At least one avoided hospital admission
was attributed to the practice pharmacist’s interventions. The GPs also reported that the practice
pharmacist had educated them about asthma.
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Table 2. The perceptions of asthma care provided by practice pharmacist.
Themes Illustrative Quotes
Satisfaction of patients, GPs
and pharmacists
“They actually made some adjustment—well the GP had made some adjustment to my
medication and both of them want to review that together with me and see how that
actually goes and whether that sort of caused much of a change in the way in which my
breathing with my asthma has actually improved a lot”. (Patient, 2016)
“One of the most satisfying things is also the asthma cycle of care. Seeing them coming
back you look at their asthma, you give their education, they’re coming back and they’re
saying they’re feeling so much better”. (Practice Pharmacist, 2016)
“I think some of the patients have really valued that and got better asthma control so that
has been really good”. (GP2, 2018)
“Patients who have poor adherence that I wasn’t aware of and their asthma is so much
better now because they’re actually taking their preventers, which is a revelation to them.
I think patients have found the interactions with [the pharmacist] very helpful around
asthma”. (GP1, 2016)
“One’s [patients] that have come in for asthma reviews have been very pleased”.
(GP1, 2018)
Improved care and avoided
hospital admission
“There is a one asthma patient that I have had who was really difficult and basically
tolerated really poorly controlled asthma. She would only come in when she was very bad.
Again, [the pharmacist] got her in and emphasised the preventative part of it, and I think
that’s prevented even hospital admissions as well as improved the lady’s quality of life”.
(GP1, 2018)
Pharmacist as an expert in
asthma care
“I think that whole process has really sharpened me up in terms of the kinds of ways that
we do provide this asthma cycle of care. She’s providing extra knowledge into that space
and I guess it’s helping the patients with their inhaler technique. She’s taught me some
things about inhaler techniques that I didn’t know”. (GP1, 2016)
“If somebody comes in for asthma, everybody, even the reception, think about me”.
(Practice Pharmacist, 2018)
4. Discussion
4.1. Summary
This pilot study demonstrated that it is feasible, acceptable and beneficial to have a pharmacist in
general practice focusing on asthma management. Following practice pharmacist review, 42% (8/19) of
patients moved from poor to well-controlled asthma, while case studies and qualitative data indicated
probable hospital admission avoidance and acceptability to stakeholders. The GPs had not previously
routinely issued asthma action plans or recorded asthma control scores for patients, so this was an
added benefit of pharmacist involvement.
4.2. Strengths and Limitations
Data from one pharmacist was analyzed, so all patients received a comparable level of care and
completion of the ACT was consistent. The practice pharmacist was a generalist and not an asthma
specialist; this can be perceived as advantageous, being more representative of likely future care
models. On the other hand, the pharmacist had additional medication review qualifications [15] and
was experienced.
We were reliant on the pharmacist accurately self-reporting activities. The general practice
population was from one city, so may not be representative of the wider Australian population.
In some countries, pharmacists are permitted to prescribe medication but this is not the case in
Australia, where this study was conducted; findings may have been different had there been pharmacist
prescribing. We acknowledge that the improvements in asthma control in our pilot study may have
been affected by other factors, such as seasonal variability of asthma triggers or interventions by
other health care professionals. The nature of the study meant there was no control group, although
previous studies with a control group have demonstrated pharmacist effectiveness in improving
asthma symptoms [16,17].
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4.3. Comparison with Existing Literature
Improvements in asthma clinical markers in this study are consistent with the improved clinical
indicators following practice pharmacist intervention in other chronic conditions [18], and with that
found in a systematic review of pharmacists’ effect on asthma control in settings not including general
practice [7]. An English study demonstrated that a specialist respiratory pharmacist visiting a general
practice could reduce asthma exacerbations and associated costs [19]. In addition, Gums et al. reported
that a physician–pharmacist collaborative asthma care model in USA primary care medical offices
reduced asthma-related emergency department visits and hospitalizations, and improved both asthma
control and quality of life [20].
All the patients who saw the pharmacist received asthma action plans, an intervention
recommended by the Australian asthma guidelines [21]. The use of written action plans to enable
patients to adjust their medication seems to be more effective in improving health outcomes than
other self-management strategies [22]; however, quality evidence is lacking [23]. A project conducted
in Minnesota urban community clinics resulted in more patients having optimal asthma control
(ACT ≥ 20), by increasing completion of asthma action plans and educating patients about using the
plan [24]. This contrasts to the findings of a review in 2017, which concluded that asthma action plans
have no effect on hospital attendance due to asthma, asthma symptom scores or adverse events [23].
Good healthcare teamwork in non-acute settings has been linked with better patient impact [25].
The practice pharmacist in this pilot study managed asthma within a multidisciplinary team to achieve
shared goals. This approach is recommended in the Australian Asthma Handbook, ‘effective asthma
management involves the whole primary care team, working with the person and also their family or
carer where appropriate’ [21]. Gums et al. determined that pharmacist and doctor collaboration can
improve asthma outcomes [20] and this is consistent with our findings.
Lack of adherence to prescribing guidelines is also associated with poor asthma control [2].
The pharmacist in this study made recommendations using prescribing guidelines. Pharmacists
have demonstrated that they can enhance adherence to guidelines in other conditions (e.g., type 2
diabetes and heart failure) [26,27], so it is reasonable to suggest that practice pharmacists may improve
adherence to asthma prescribing guidelines.
4.4. Implications for Research
Future well-designed studies are required to confirm the promising results reported here and
extend to outcome measures such as hospital admissions, quality of life and cost-effectiveness.
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Appendix A
Appendix A.1 Case Study One
The pharmacist saw a 4-year-old boy and his mother for a GP-initiated asthma review. His medical
history included hayfever and eczema. His medication use included: fluticasone 50 mg metered dose
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inhaler two puffs twice a day via spacer, montelukast 4mg once a day, salbutamol 100 mg metered
dose inhaler two puffs when needed for breathlessness via spacer. The patient’s mother reported that
her son had an asthma exacerbation the previous week, probably caused by a cold. She administered
montelukast 4 mg daily for 3 days and then stopped because her son had become aggressive and
had started having tantrums. The pharmacist explained that behavioral changes can be a rare side
effect from the montelukast. Following discussion with the GP, another trial of montelukast was
recommended when the child’s asthma was well-controlled. Over the course of a week, the boy’s
asthma improved (ACT 11/25 to 19/25). The pharmacist counselled the patient and his mother about
asthma medication, triggers and symptoms. One of the identified triggers was uncontrolled hayfever
with nasal congestion being his main symptom. The pharmacist suggested a trial of a beclomethasone
nasal spray and advised the boy and his mother about limiting time outdoors when the pollen count
was high. Asthma inhaler technique was optimised, and written information about asthma and inhaler
technique was provided. The mother was unaware of the need to shake the inhaler prior to use, this
was reinforced by the pharmacist. The patient and his mother were counselled about the asthma action
plan written by the pharmacist, including that if asthma worsens then to start fluticasone.
Appendix A.2 Case Study Two
A 46-year-old female had attended the hospital emergency department (ED) with an asthma
exacerbation one week before her unscheduled initial pharmacist consultation. Her medications were
salbutamol CFC-Free 100 mg/dose inhaler 2–6 puffs four times a day and when needed, ipratropium
21 mg/dose inhaler 4 puffs up to four times a day, fluticasone/eformoterol 250/10 inhaler 2 puffs twice
a day. Her ACT score was 6/25 at review. The pharmacist provided education about asthma symptoms,
discussed possible triggers and provided medication counselling using the lay terms ‘reliever’ and
‘preventer’. The pharmacist optimised inhaler technique and provided a GP-approved asthma action
plan. The patient was reviewed by the pharmacist one week later and her ACT score had improved by
7 points (13/25). The pharmacist recommended that salbutamol (100 microgram/dose) be reduced
from 6 to 4 puffs four times a day and when needed, with the plan to reduce further as asthma control
improved. The pharmacist reinforced the importance of continuing with twice daily use of the steroid
inhaler. The asthma action plan was adjusted accordingly.
Three weeks later the patient presented to the pharmacist with worsening of asthma (ACT 7/25).
Following refusal to attend ED, the pharmacist collaborated with the GP to initiate oral prednisolone.
Since the pharmacist involvement in her asthma care there have been no hospital attendances;
whereas in the same timeframe during the previous year there were two asthma-related
ED attendances.
Appendix A.3 Case Study Three
A 62-year-old male had a practice pharmacist appointment for a chronic obstructive pulmonary
disease (COPD) review. He was an ex-smoker with no other chronic conditions. His current
medications were tiotropium dry powder inhaler 18 mg daily, indacterol dry powder inhaler
150 micrograms daily, and salbutamol 100 mg 2 puffs when needed for breathlessness. The pharmacist
suspected that the patient may have undiagnosed asthma. The pharmacist administered the COPD
assessment test (CAT) [28] with the patient. The COPD CAT assesses current health status relating to
COPD and impact on quality of life. It is eight questions, each with scores of 0–5, and the maximum
total score of 40 [29]. The COPD CAT score relates to impact of COPD and are considered as very
high (> 30), high (> 20), medium (10–20) and low (< 10) [29]. The COPD CAT score for the patient
was 21. He was experiencing shortness of breath (SOB) and had disrupted sleep. His triggers were
listed as cold and flu but the SOB also worsened when he was exposed to dust at work. In consultation
with the GP, the practice pharmacist advised the patient to trial an inhaled corticosteroid, ciclesonide
80 mg metered dose inhaler, 2 puffs daily using a spacer. The practice pharmacist counselled the
patient on his new medication and inhaler technique. The pharmacist wrote an asthma action plan and
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explained to the patient how to use the plan. Using the nSpire™ PiKo-6 electronic FEV1/FEV6 meter,
the pharmacist assessed respiratory function prior to commencement of the inhaled corticosteroid
using the patient’s height (170 cm) to determine predicted values (see Table A1).
Two weeks later, the pharmacist reviewed the patient’s response to the inhaled corticosteroid
trial (COPD CAT score = 0/40 and asthma ACT = 20/25). His respiratory function tests were repeated
(see Table 1). The diagnosis was changed from COPD to asthma as a result of the pharmacist review.
In consultation with the GP, the practice pharmacist advised the patient to stop tiotropium and later
indacterol. The asthma action plan was adjusted by the pharmacist accordingly. The pharmacist and
patient discussed asthma symptoms, triggers and inhalers.
Table A1. Respiratory function test results.
Test Predicted Pre Corticosteroid (% Predicted) Post Corticosteroid (% Predicted)
FEV1 3.01 2.22 (73%) 3.29 (109%)
FEV6 3.75 3.05 (81%) 4.21 (112%)
FEV1/FEV6 0.73 0.78
PEFR 471 469
FEV1 is forced expiratory volume in 1 s; FEV6 is forced expiratory volume in 6 s (used as an alternative to forced
vital capacity); PEFR is peak expiratory flow rate.
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